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Abstract
Background: Cholesterol content of cerebral membranes is tightly regulated by elaborate mechanisms that
balance the level of cholesterol synthesis, uptake and efflux. Among the conventional regulatory elements, a recent
research focus has been nuclear receptors, a superfamily of ligand-activated transcription factors providing an
indispensable regulatory framework in controlling cholesterol metabolism pathway genes. The mechanism of
transcriptional regulation by nuclear receptors such as LXRs involves formation of heterodimers with RXRs. LXR/RXR
functions as a sensor of cellular cholesterol concentration and mediates cholesterol efflux by inducing the
transcription of key cholesterol shuffling vehicles namely, ATP-binding cassette transporter A1 (ABCA1) and ApoE.
Results: In the absence of quantitative data from humans, the relevance of expression of nuclear receptors and
their involvement in cerebral cholesterol homeostasis has remained elusive. In this work, new evidence is provided
from direct analysis of human postmortem brain gene and protein expression suggesting that RXRa, a key
regulator of cholesterol metabolism is differentially expressed in individuals with dementia. Importantly, RXRa
expression showed strong association with ABCA1 and ApoE gene expression, particularly in AD vulnerable regions.
Conclusions: These findings suggest that LXR/RXR-induced upregulation of ABCA1 and ApoE levels may be the
molecular determinants of cholesterol dyshomeostasis and of the accompanying dementia observed in AD.
Introduction
Differential control of gene expression is an important
means by which cells respond to physiological and
environmental stimuli. Nuclear receptors comprise a
superfamily of ligand regulated, DNA-binding transcrip-
tion factors that can both activate and repress gene
expression [1]. The liver X receptors (LXRs) are type II
nuclear receptors, initially identified as orphan nuclear
receptors, because their natural ligands were not known
[2,3]. LXRs have been deorphanized or adopted follow-
ing the discovery of oxysterols (hydroxylated derivatives
of cholesterol) as their endogenous ligands [3,4]. Two
LXR isoforms are known, namely LXRa and LXRb with
distinct tissue distributions [5]. LXRa expression is rela-
tively restricted to tissues involved in lipid metabolism,
such as liver and intestine [6,7], whereas LXRb is
ubiquitously expressed. Both LXR isoforms are
expressed in the brain [5]. LXRb expression, in particu-
lar is 2-5 fold higher in the brain than in liver [8].
The mechanisms of transcriptional regulation by LXRs
involve formation of heterodimers with retinoid X
receptor (RXR). RXR is another deorphanized nuclear
receptor, activated by 9-cis-retinoic acid (a vitamin A
derivative) [9]. Upon heterodimerization, LXR/RXR bind
to specific DNA sequences called LXR-responsive ele-
ments (LXREs) in the target genes [10]. In the absence
of a ligand, LXRs bound to cognate LXREs, are in com-
plex with corepressors such as silencing mediator of
retinoic acid and thyroid hormone receptor (SMRT)
[11] and nuclear receptor corepressor (N-CoR) [12],
consequently, the transcription of target genes is
repressed. Receptor ligation induces conformational
changes in the ligand binding domain which mechanisti-
cally facilitates the release of corepressors and the
recruitment of coactivators and histone acetyltransferase
(HAT), the enzyme that acetylates lysine amino acids on
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acetyl CoA and is generally associated with transcrip-
tional activation [13,14] (Figure 1). Interestingly, LXR/
RXR receptors exhibit the “phantom ligand effect,” the
ability of ligand-induced allosteric signal transmission by
nuclear receptors to activate the unliganded heterodi-
meric partners [15]. These heterodimers are also
referred to as permissive because the complex can be
activated by ligands of either partner. These unique fea-
tures allow multiple ligand-mediated pathways to be
integrated into a transcriptional response.
Studies over the last decade have established LXRs as
master regulators of lipid metabolism. LXR mediates activa-
tion of target genes such as sterol responsive element bind-
ing protein 1c (SREBP1c), a master transcription factor that
controls the entire fatty acid biosynthetic pathway [16],
lipid transporters including members of the superfamily of
ATP-binding cassette (ABC) transporters such as ABCA1
[17-19], apolipoproteins (ApoE, ApoD) [20,21] and lipopro-
tein modifying enzymes (cholesteryl ester transfer protein
(CETP) and phospholipid transfer protein (PLTP) [22,23].
In addition, primary astrocyte cultures treated with syn-
thetic LXR ligands exhibit increased cholesterol efflux and
elevated expression of LXR target genes including ABCA1
and ApoE [8,24,25]. LXRa/b knockout mice show a variety
of CNS defects including lipid accumulation, astrocyte pro-
liferation and disorganized myelin sheaths [26,27].
The expression of RXRs has been observed by immu-
nohistochemistry and in situ h y b r i d i z a t i o ni nm o u s e
brain [28-30]. There are three isoforms of RXRs: RXRa,
RXRb,R X R g.R X R a and b are most prevalent in the
neocortex and hippocampus while RXRg expression is
restricted to the neocortex [31].
Analysis of data from a large-scale microarray study of
postmortem brain specimens obtained from multiple
brain regions of elderly patients with varying severity of
dementia [32] indicated significant changes in RXR gene
expression [33,34]. Observed changes in gene expression
were isoform-specific with more robust Alzheimer’sd i s -
ease (AD)-associated changes observed in RXRa levels. In
particular, the dysregulated expression was most obvious
in AD vulnerable regions such as inferior temporal gyrus
(area 20) and superior temporal gyrus (area 22) and in the
hippocampus, but not in primary visual cortex (area 17)
which is relatively spared from age related or AD-asso-
ciated neurodegeneration [35-40]. In addition, changes in
LXR/RXR target genes, ABCA1 and ApoE in AD brains as
a function of the increasing severity of dementia and neu-
rofibrillary pathology were also observed [33,34,41]. The
significance of these results is twofold. First, expression
levels of nuclear receptors and their target genes have not
been previously reported in a single cohort of clinically,
neuropsychologically and neuropathologically well-charac-
terized AD and control individuals with minimal mRNA
variability, known medical history and absence of pro-
tracted agonal state. Second, ABCA1 and ApoE are not
only LXR/RXR target genes but also the major determi-
nants of net cholesterol flux. These novel findings pro-
vided an impetus to study LXR/RXR gene and protein
expression using more quantitative technique. To this end,
we analyzed LXRb and RXRa mRNA expression in the
hippocampus and inferior temporal gyrus (area 20) of a
large series of cases at different stages of dementia and AD
associated neuropathology by quantitative PCR. Because
mRNA and protein levels can diverge significantly through
post-transcriptional regulation, Western blotting was used
to quantify protein levels in the hippocampus of a subset
of the postmortem brain specimens used in PCR analyses.
Results
qPCR analysis of RXRa expression in area 20
In order to perform post-assay analyses based on a clini-
cal index of disease severity, the subjects were classified
with respect to the clinical dementia rating (CDR) score
Figure 1 Schematic diagram of LXR/RXR activation mechanism (adapted from the references cited above).I nt h ea b s e n c eo fal i g a n d ,
LXR/RXR heterodimers are bound to the LXREs in the promoter region of target genes and in complex with corepressors (SMRT or NCoR).
Ligand binding (e.g., oxysterols) induces a dissociation of corepressors and recruitment of coactivators and the target gene expression is
induced.
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duals with and without dementia {i.e., CDR 0 vs. CDR
0.5-5) showed higher levels of RXRa gene expression in
individuals with dementia (F1,84 = 15.48, p < 0.0005; Fig-
ure 2). Comparisons of individuals with and without
AD-associated neuropathology also showed more RXRa
gene expression as a function of increasing neuritic pla-
que (NP) density (F1,84 = 3.36, p = 0.035) but not Braak
neuropathological stages (F1,84 =1 . 4 2 ,p =0 . 2 3 7 ;F i g u r e
2). These results suggest that RXRa expression is dysre-
gulated in the earliest quantified stage of dementia and
AD-associated neuropathology. The partial correlations
of RXRa mRNA expression demonstrated significant
associations with CDR (r = 0.301, df = 84, p = 0.005).
However, the linear association of RXRa mRNA levels
with either Braak neuropathological stages (r = 0.193, df
=8 4 ,p = 0.076) or NP density (r = 0.132, df = 84, p =
0.225) was not significant, indicating that RXRa levels
are elevated at the earliest stages of dementia and
remain near maximally elevated throughout the course
of dementia. In ANCOVAs controlling for age and RNA
integrity number (RIN), CDR (F5,80 =3 . 6 2 ,p = 0.005)
and NP density (F4,81 = 3.55, p = 0.010) showed
significant associations with RXRa mRNA expression.
Whereas, the association of Braak neuropathological
stages with RXRa gene expression was not significant
(F6,79 = 0.85, p = 0.536). Figure 3 presents the estimated
means and SEM from the ANCOVAs, adjusting for the
covariates.
qPCR analysis of LXRb expression in area 20
Gene expression analysis in controls and individuals
with dementia (CDR ≥ 0.5) or AD-associated neuro-
pathology showed higher levels of LXRb gene expression
(F1,84 =3 . 1 4 ,p = 0.040) only in individuals with varying
dementia severity (Figure 2). The partial correlation ana-
lysis showed that after controlling for age and PMI,
LXRb mRNA expression was not significantly associated
with CDR (r = 0.045, df = 84, p = 0.684), Braak neuro-
pathological stages (r = 0.007, df = 84, p = 0.951) or NP
density criteria (r = 0.032, df = 84, p =0 . 7 7 1 ) .T h e r e
was a significant increase in LXRb gene expression with
the earliest signs of dementia (CDR 0.5), however, in
ANCOVAs the association of CDR (F5,80 =1 . 3 0 ,p =
0.274) with LXRb gene expression was not significant.
Similarly, the association of Braak neuropathological
score (F6,79 =0 . 3 0 ,p = 0.938) or NP density (F4,81 =
1.83, p = 0.132) with LXRb gene expression was not sig-
nificant. Figure 3 presents the estimated means and
SEM from the ANCOVAs, adjusting for the covariates.
qPCR analysis of RXRa expression in hippocampus
Comparisons of controls and cases presenting with vary-
ing degree of dementia or AD-associated neuropathol-
ogy showed higher levels of RXRa gene expression
associated with increases in CDR (F1,69 =6 . 1 4 ,p =
0.008) but not with Braak neuropathological staging
(F1,69 =0 . 1 5 ,p = 0.703) or NP density (F1,69 =0 . 5 2 ,p =
0.474; Figure 4). RXRa mRNA expression demonstrated
significant linear associations with CDR (r = 0.251, df =
69, p = 0.035) but not with Braak neuropathological
stages (r = 0.127, df = 69, p = 0.290) or NP density (r =
0.021, df = 69, p = 0.861). In ANCOVAs controlling for
age and pH, when CDR (F5,65 = 1.83, p = 0.119), Braak
neuropathological stages (F6,64 = 0.59, p =0 . 7 4 0 )a n d
NP density (F3,67 = 0.53, p = 0.667) were treated as cate-
gories, the associations were not significant. Figure 5
presents the estimated means and SEM from the
ANCOVAs, adjusting for the covariates. Overall,
changes in RXRa gene expression aligned significantly
with clinical measure of the disease compared to the
neuropathological parameters.
qPCR analysis of LXRb expression in the hippocampus
Gene expression analysis in controls and cases with
dementia or AD-associated neuropathology did not
reveal significant difference in LXRb gene expression
Table 1 Group classifications for gene expression
analyses
Gene Expression Analysis
Number of
individuals
CDR Groups Dementia Severity Hippocampus Area
20
0 No dementia 18 18
0.5 Questionable dementia 13 13
1 Mild dementia 9 8
2 Moderate dementia 9 13
3 Severe dementia 12 18
4-5 Very severe/terminal
dementia
12 18
Braak Groups Braak stages
0 None 7 9
I Mild transentorhinal 8 9
II Severe transentorhinal 15 16
III Limbic 10 12
IV Limbic/Hippocampal CA1 8 8
V Isocortical 12 15
VI Isocortical/Primary sensory
areas
13 19
NP Density
Groups
Plaques (number/mm
2)
0 0 24 26
1 1-5 10 13
2 6-10 20 23
3 11-20 14* 14
4 21 and more 5* 12
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mRNA expression did not show association with CDR (r
=0 . 0 2 5 ,d f=7 0 ,p = 0.835), Braak neuropathological
stages (r = 0.029, df = 70, p = 0.809) or NP density (r =
0.116, df = 70, p = 0.334). In ANCOVAs controlling for
age, when CDR (F5,66 =0 . 4 8p = 0.794), Braak neuro-
pathological stages (F6,65 = 0.94, p = 0.472) and NP den-
sity (F3,68 = 1.27, p = 0.290) were analyzed as categories,
t h el a c ko fa s s o c i a t i o n sw e r e similarly evident. Figure 5
presents the estimated means and SEM from the
ANCOVAs, adjusting for the covariates.
RXRa protein expression
Western blot analysis revealed robust RXRa protein
expression in tissue homogenates from the hippocampus
(Figure 6A). RXRa protein expression was highly
Figure 2 RXRa (Black bars) and LXRb mRNA (white bars) expression in individuals with and without dementia or AD-associated
neuropathology in area 20. Mean values ± SEM are shown. *, p < 0.05; ****, p < 0.0001. Number within the parentheses indicates the
individuals within each group.
Figure 3 Normalized RXRa (Black bars) and LXRb mRNA (white bars) expression in area 20 plotted against CDR scores, Braak
neuropathological stages and NP density. ANCOVA was used to compare gene expression in individuals with varying degree of dementia
(CDR 0.5-5) and AD associated neuropathology (Braak stage I-VI, NP density 2-5) relative to the control group. Mean values ± SEM are shown. *,
p < 0.05; **, p < 0.01. Number within the parentheses indicates the individuals within each disease severity group.
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levels of RXRa. These findings suggest coordinated tran-
scriptional and translational modulation of RXRa during
the course of AD. Partial correlation analysis of RXRa
protein expression showed strong associations with CDR
(r = 0.525, df = 29, p = 0.002) but not with Braak scores
(r = 0.266, df = 29, p = 0.147) or NP density (r = 0.077,
df = 29, p = 0.681). Even after controlling for Braak
score and NP density, RXRa protein expression was sig-
nificantly correlated with CDR (r = 0.500, df = 27, p =
0.006). As was the case for gene expression, in ANCO-
VAs for protein expression, there was significant
Figure 4 RXRa (Black bars) and LXRb mRNA (white bars) expression in individuals with and without dementia or AD-associated
neuropathology in hippocampus. Mean values ± SEM are shown. **, p < 0.01. Number within the parentheses indicates the individuals within
each group.
Figure 5 Normalized RXRa (Black bars) and LXRb mRNA (white bars) expression in hippocampus plotted against CDR scores, Braak
neuropathological stages and NP density groups. ANCOVA was used to compare gene expression in individuals with varying degree of
dementia (CDR 0.5-5) and AD-associated neuropathology (Braak stage I-VI, NP density 2-5) relative to the control group. Mean values ± SEM are
shown. *, p < 0.05; **, p < 0.01. Number within the parentheses indicates the individuals within control groups and each of the disease severity
group.
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6B), but not with Braak scores (F3,27 =0 . 8 7 4 ,p =0 . 4 6 7 )
or NP density (F1,29 = 0.172, p = 0.681). Significantly
more RXRa protein expression was observed in cases
with dementia (CDR ≥ 0.5) relative to controls (CDR =
0) (F1,29 = 8.27, p = 0.007).
Association with ABCA1, ApoE, and LRP gene expression
The association of ABCA1, ApoE and LRP, the major
determinants of net cholesterol flux, with RXRa mRNA
expression was determined using partial correlation ana-
lysis. RXRa mRNA expression indicated strong associa-
tion with mRNA levels of ABCA1 (r = 0.531, df = 83, p
< 0.0001; Figure 7A), ApoE (r = 0.622, df = 84, p <
0.0001; Figure 7B) and LRP in area 20 (r = 0.888, df =
84, p < 0.0001; Figure 8A). RXRa gene expression in the
hippocampus also showed strong associations with
ABCA1 (r = 0.436, df = 69 p < 0.0005), ApoE (r =
0.446, df = 69 p < 0.0001) and LRP gene expression (r =
0.697, df = 69 p < 0.0001; Figure 8B).
Discussion
This study explored the expression profile of the master
regulators of lipid metabolism in two of the most vul-
n e r a b l er e g i o n so ft h eA Db r a i n .T h ep r i m a r yf i n d i n g
was that RXRa levels increased at the very earliest stage
of dementia and remained elevated, in general, through-
out the course of the disease. In addition, these eleva-
tions in gene and protein expression were more strongly
associated with the development of AD-associated
Figure 6 Western blot analysis of RXRa in the hippocampus of cognitively intact controls and subjects with varying severity of
dementia. A, Representative immunoblots of RXRa protein expression are shown. Total tissue homogenates were separated by reducing SDS-
PAGE and probed with rabbit anti-RXRa and mouse anti-VCP antibodies. Tissue lysate from each subjects were loaded in triplicate and pooled
tissue lysate (first 4 lanes) were run in quadruplicates. B, Protein quantification was done by assessing the ratio of RXRa and VCP signal. Mean
values ± SEM are shown. *, p < 0.05; **, p < 0.01. Number within the parentheses indicates the individuals within each group.
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logic lesions of AD. In order to identify earliest tran-
scriptional changes during the course of AD
progression, study individuals were grouped based on
dementia severity (CDR score) at the time of death, pro-
gression of NFT pathology and the severity of NP
pathology. This strategy allowed us to correlate expres-
sion of nuclear receptors to cognitive and pathological
indices of AD, with an emphasis on individuals present-
ing earliest signs of AD. These approaches revealed a
previously unrecognized transcriptional dysregulation of
RXRa in AD. Specifically, alteration in gene expression
in both regions was strongly correlated with cognitive
impairment. Additionally, weo b s e r v e dh i g h l yc o o r d i -
nated upregulation of RXRa protein in AD hippocam-
pus. Along with the identification of altered RXRa
expression, this study highlights closely correlated
expression of RXRa with the downstream target genes
that have been previously implicated in AD pathogenesis
including ApoE and ABCA1. One parsimonious inter-
pretation of these findings is that changes in the expres-
sion of RXR become evident before the advent of the
neuropathological hallmarks of AD and raise the possi-
bility that the upregulation of RXR may be responsible
for the changes in subsequent progressive cholesterol
dyshomeostasis and AD neuropathology. However,
because of the postmortem nature of the current study,
the results of this study do not address directly whether
the elevated levels of LXR/RXR in dementia are causal,
secondary or bystander. It is also important to note that
although we interpret transcriptional changes as a func-
tion of the severity of dementia or neuropathology to
represent disease progression, the cross-sectional nature
of this postmortem study, like all postmortem studies,
permits only the inference of progression rather than its
direct measurement. In addition, the reported results
are based on assays of brain tissue homogenates, and
therefore cannot inform on the cellular localization of
the dysregulated gene expression or the laminar identity
of the affected cells.
Although the pathogenesis of AD is not fully under-
stood much direct and circumstantial evidence suggests
that many of the genes and pathways involved in choles-
terol and/or lipoprotein metabolism in brain are also
intimately involved in the pathogenesis of AD. Most
notable are ApoE, the principal cholesterol carrier pro-
tein in the CNS, and ABCA1, a protein that modulates
the efflux of cellular cholesterol and phospholipids to
lipid-deficient apolipoprotein acceptors such as ApoE
[42-44]. Interestingly, we have observed significant
Figure 7 Association between RXRa and target gene expression in area 20.A .RXRa gene expression is strongly associated with ABCA1
gene expression (r = 0.531, df = 83, p < 0.0001). B. RXRa gene expression is strongly associated with ApoE gene expression (r = 0.622, df = 84, p
< 0.0001).
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tissues specimens as those described here [33,34,41].
Although, in the hippocampus, significant increase in
RXRa mRNA level was observed in individuals with
moderate to severe dementia, significant increase in
RXRa protein expression was evident in individuals at
an earlier stage of cognitive decline. Consequently, even
small changes in RXRa mRNA expression potentially
result in relatively large changes in RXRa protein.
Because RXRa expression is strongly correlated with
transcriptional changes in both ABCA1 and ApoE,i ti s
conceivable that the variance in RXRa,w h i c hi sn o t
enough for strong association with CDR to be detected,
could nevertheless induce expression of the target genes
to the extent that significant correlations with earliest
cognitive and neuropathological markers are obvious.
These results are particularly intriguing in light of the
fact that both ABCA1 and ApoE are under transcrip-
tional regulation of the RXR/LXR signaling pathway.
Together, these findings suggest that RXR/LXR-
mediated alterations in ApoE and ABCA1 levels can
modulate cholesterol metabolism and consequently the
risk for AD.
In AD, cholesterol dyshomeostasis has been associated
with the processing of amyloid precursor protein (APP)
to generate neurotoxic Ab [45]. Given the critical role
played by LXR/RXR in the regulation of cellular choles-
terol homeostasis, and their expression in multiple brain
types (albeit with significant cell type and brain region
expression differences), numerous studies have focused
on the ability of LXR/RXRs to regulate amyloidogenic
processing of APP. However, contradictory results have
been reported on Ab metabolism following treatment of
cultured cells with LXR agonists [24,46,47]. The reason
for the discrepancies may be related to differences
between the expression of APP under physiologic condi-
tions vs. its expression in mutant cells, and the extent to
which membrane cholesterol transport was modified
under the different in vitro conditions. In vivo studies
using a synthetic LXR agonist, TO-901317, were more
definitive in suggesting decreased Ab deposition in the
brains of APP transgenic mice [48,49]. Interestingly,
TO-901317 has been shown to inhibit g-secretase inde-
pendent of LXR/RXR activation [50]. In addition, TO-
901317 is also a farnesoid X receptor and pregnane X
receptor agonist [51,52]. This raises concerns about the
specificity of TO-901317 and the interpretation of stu-
dies using TO-901317 mediated LXR/RXR activation.
Finally, LXR/RXR-mediated cholesterol homeostasis is
differentially regulated in mice and humans. These
Figure 8 Association between RXRa and LRP gene expression.A .RXRa gene expression is strongly associated with LRP gene expression in
area 20 (r = 0.89, df = 84, p < 0.0001). B. RXRa gene expression is strongly associated with LRP gene expression in hippocampus (r = 0.70 df =
69, p < 0.0001).
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cial outcomes to LXR/RXR-mediated transcriptional
regulation. In mice but not in primates, hepatic choles-
terol 7a-hydroxylase is upregulated by LXR [4,53,54].
Mice do not express CETP. Direct induction of CETP in
human cell lines and two CETP-containing animal mod-
els, Syrian hamsters and long-tailed macaque monkeys,
is accompanied by a significant increase in LDL choles-
terol levels that was not previously observed in mice
[23,55,56]. These findings emphasize the need to exer-
cise caution when extrapolating results from animal stu-
dies to humans, especially when significant species-
specific differences have been identified in the underly-
ing biological processes. It is noteworthy that in the cur-
rent systematic analysis, LXR/RXR expression levels
were not associated with elevations in NP counts. It
may be plausible that change in RXRa expression may
influence soluble toxic forms or fractions of Ab,y e ti t
does not correlate with NP density because RXRa has a
monotonic pattern of expression, whereas NPs continue
to increase in density.
LXRs are activated by endogenous oxysterols, the
most potent of which include 24, 25-epoxycholesterol,
24-OH, and 27-hydroxycholesterol. The role of 24-OH
(also known as cerbrosterol) is particularly intriguing
because it is primarily produced in the brain by neuron
specific CYP46 [57] and its level is increased in plasma
and CSF during early stages of AD [58,59]. 24-OH has
been shown to activate LXRs and dramatically elevate
ABCA1 expression in both neurons and astrocytes
[8,25,60]. Therefore increased expression of ABCA1 and
ApoE in incipient AD might be a reflection of 24-OH
mediated increased LXR/RXR activation. Paradoxically,
24-OH level is reduced in late stages of AD [61], sug-
gesting that sustained increases in the expression of
LXR/RXR target genes in relatively late stages is modu-
lated by other factors.
LXRb heterodimer with RXRa i st h eo n l yn u c l e a r
receptor complex known to date that can be activated
in the absence of a ligand, via a mechanism termed
“dimerization-induced activation” [62-64]. In this model
of LXR transactivation, the interaction of RXR with LXR
can allosterically activate LXR by inducing a conforma-
tional change in its ligand-binding domain. The relative
expression levels of both receptors are therefore likely
to regulate signaling via LXRb and RXRa in a highly
complex fashion. Indeed, in transient transfection stu-
dies LXR/RXR activation is only observed upon RXRa
cotransfection [3,65,66], which results in a higher num-
ber of LXRb/RXRa heterodimers for which coregulators
would have to compete. Because the activated LXRb/
RXRa heterodimer also exhibits dual ligand permissive-
ness and synergism [62,67], its net transcriptional poten-
tial depends on the occurrence of dimerization-induced
activation and ligand availability. Consistent with this
idea, the overexpression of RXRa reported here could
allosterically activate LXRb and consequently increase
target gene expression, in addition to that induced by
24-OH. Recently, LRP has been shown to participate in
ABCA1 expression by relieving LXR/RXR repression
(via cPLA2 activation) [68]. Strong association of LRP
gene expression with that o fL X Ra n dR X Rs u g g e s t s
that LRP modulates not only LXR/RXR activation but
also their transcription. Alternatively, LRP may be an
LXR/RXR target gene.
Conclusions
Based on previous studies where a drastic reduction in
cholesterol level decreased Ab production [69-71] and
owing to their ability to induce expression of genes
mediating cholesterol efflux, LXR/RXR heterodimers
have emerged as potential targets for AD therapeutics
[72]. However, there are obvious contradicting reports
of increased Ab generation upon lowering brain choles-
terol level [73,74]. More importantly, the hippocampus
of AD cases presents a moderate, yet significant, reduc-
tion in membrane cholesterol [75]. These latter findings
are consistent with increased expression of RXRa
reported here. Taken together, increased expression of
RXRa and concomitant activation of LXR/RXR can
modulate ABCA1 and ApoE gene expression. Increased
levels of ABCA1 and ApoE may be the molecular deter-
minants of cholesterol dyshomeostasis and accompany-
ing dementia observed in AD.
Materials and methods
Study Cohort
The cohort included in this study was part of a larger
clinical and neuropsychological investigation of early
AD. These individuals were extensively evaluated for
their cognitive function. Their cognitive status during
the 6 months proximal to death was used to define the
absence, presence and extent of dementia at the time of
death, as previously described [76-78]. Cases were
selected from a pool of over 600 donors with either no
discernable neuropathology or only those neuropatholo-
gical lesions associated with AD alone (e.g., exclusion of
cases with vascular lesions, Lewy body inclusions, nor-
mal pressure hydrocephalus). Because postmortem inter-
vals (PMI) [79,80] and tissue pH (a proxy measure for
agonal state) [81,82] are important issues for consistency
and reproducibility of quantitative gene and protein
expression studies, brain samples were included from
cases who met the following criteria only: postmortem
d e l a yo fl e s st h a n2 4h o u r s ,b r a i nt i s s u ep Ho f6 . 3o r
greater no perimortem coma longer than 6 hrs, no evi-
dence of seizures in the 3 months preceding death. Con-
trols were derived from persons who, on extensive
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nation and caregiver interview, showed no evidence of
neurological or neuropsychiatric diseases, died of natural
causes (myocardial infarction, various non-brain non-
hepatic cancers, and congestive heart failure) and had
no discernable neuropathology [83]. None of the sub-
jects had a history of licit or illicit drug abuse (tobacco
use excepted). All diagnostic and cognitive assessment
procedures were approved by the Mount Sinai Medical
Center (New York, NY)/J. J. Peters Veterans Administra-
tion Medical Center (Bronx, NY) Institutional Review
Boards, and postmortem consent for autopsy and
research use of tissue was obtained from the next of kin
or a legally authorized official.
Classification of Subjects into Dementia Severity Groups
In order to perform post-assay analyses based on a
clinical index of disease and dementia everity, the sub-
jects were classified with respect to the CDR score at
the time of death [84-87] (Table 1). CDR is a scale
that objectively stages dementia severity from 0-5 with
0 representing no dementia, 0.5 representing question-
able dementia or mild cognitive impairment and 1-5
representing gradations of dementia severity from mild
to terminal. The assessments, on which these classifi-
cations were based, were performed blind to clinical or
neuropathological disease diagnosis. Table 2 describes
the sample size, sex, age at the time of death, pH and
PMI of the study cohort when grouped on the basis of
CDR.
Neuropathological Assessment
The neuropathological assessment procedures used have
been previously described in detail [76,78]. Neuropatho-
logical assessments were performed on the right hemi-
sphere and consisted of microscopic assessment of
paraffin embedded blocks from multiple brain regions
using hematoxylin and eosin, modified Bielschowski,
modified thioflavin S, and anti-amyloid, anti-tau tau
when necessary. All neuropathology data regarding the
extent and distribution of neuropathologic lesions were
collected blind to the subject’s dementia status. Speci-
mens for this study were dissected from the frozen,
never-thawed, left hemisphere, using previously
described procedures [88].
For pathologic staging of AD neurofibrillary tangle
density was assessed using the Consortium to Establish
aR e g i s t r yf o rA l z h e i m e r ’s Disease (CERAD) [89,90]
criteria, NFTs were evaluated using the criteria by
Braak and Braak [91] (Table 1). Neuritic plaques (NPs)
were identified as the dystrophic neurites arranged
radially and forming a discrete spherical lesion about
30 mm in diameter with amyloid cores. NP groups in
Table 1 reflect a composite score of NPs counts in 5
cortical regions. The composite measure of cortical NP
density was used to reflect better the general level of
disease severity and to match more closely to the glo-
bal assessment of cognitive function measured by the
CDR.
RNA Isolation
Total RNA was isolated from 50 mg of microdissected
pulverized frozen brain samples from inferior temporal
gyrus and the hippocampus with the guanidinium iso-
thiocyanate method [92] using ToTALLY RNA kits
(Ambion, Austin, TX) according to the manufacturer’s
protocol as described previously [93]. The quality of the
isolated total RNA for each case was assessed using a
combination of 260 nm/280 nm ratio obtained spectro-
photometrically (Beckman Instruments, Fullerton, CA)
and by Bioanalyzer 2100 (Agilent Technologies, Palo
Alto, CA) before proceeding with cDNA synthesis. Only
specimens with an RIN ≥ 5.5 were included in the
analyses.
Table 2 Demographic details of study cohort stratified with respect to CDR (Clinical Dementia Rating) groups
Characteristics Area CDR 0 CDR 0.5 CDR 1 CDR 2 CDR 3 CDR4-5
Total subjects* Hipp 18 13 9 9 12 12
Area 20 18 13 8 13 18 18
Gender (men/women) Hipp 7/11 6/7 3/6 0/9 3/9 3/9
Area 20 6/12 7/6 3/5 1/12 7/11 8/10
Age (years) Hipp 75.2 ± 3.5 85.4 ± 2.7 83.4 ± 3.4 87.9 ± 2.0 88.8 ± 1.7 85.0 ± 1.9
Area 20 77.0 ± 3.9 85.5 ± 2.8 85.6 ± 3.8 87.6 ± 2.0 86.2 ± 8.5 84.2 ± 2.5
Brain pH Hipp 6.43 ± 0.04 6.43 ± 0.07 6.31 ± 0.1 6.38 ± 0.09 6.34 ± 0.05 6.39 ± 0.07
Area 20 6.42 ± 0.05 6.42 ± 0.07 6.35 ± 0.11 6.39 ± 0.08 6.43 ± 0.05 6.36 ± 0.05
RNA integrity number (RIN) Hipp 6.6 ± 0.1 6.2 ± 0.1 6.2 ± 0.2 6.2 ± 0.2 6.1 ± 0.1 6.2 ± 0.1
Area 20 6.9 ± 0.1 6.9 ± 0.1 6.7 ± 0.2 6.3 ± 0.2 6.9 ± 0.2 6.3 ± 0.1
Postmortem interval (minutes) Hipp 713 ± 137 393 ± 85 264 ± 39 336 ± 66 276 ± 40 332 ± 80
Area 20 574 ± 109 381 ± 91 325 ± 52 358 ± 64 244 ± 29 310 ± 73
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cDNA synthesis was performed with iScript cDNA
Synthesis kit (BioRad Laboratories, Hercules, CA) which
uses both random and poly-dT priming for the reverse
transcription (RT) reaction. Total RNA (1 μg) was
employed for each 20 μl reaction. The resulting cDNA
was diluted 25 times for qPCR.
qPCR
LXRb and RXRa mRNA expression was measured by
quantitative polymerase chain reaction (qPCR) using an
ABI Prism 7700 Sequence Detector (Applied Biosystems,
Foster City, CA) and gene-specific fluorogenic TaqMan®
probes (Applied Biosystems). Each 20 μl PCR reaction
contained 5 μlo ft h er e l e v a n tc D N A ,2 0 XT a q M a n ®
assay (used at a final concentration of 0.5X), and 10 μl
of TaqMan® Universal PCR Reaction Mix which con-
tains ROX as a passive internal reference (Applied Bio-
systems). The thermal cycling program consisted of 2
min at 50°C, 10 min at 95°C, followed by 40 cycles of 15
s at 95°C and 1 min at 60°C. The reactions were quanti-
fied by selecting the amplification cycle when the PCR
product of interest was first detected (threshold cycle,
Ct). Tests of primers and probes sensitivity and assay
linearity were conducted for all real-time PCR assays by
amplification of mRNA in 10-fold serial dilutions of
pooled as previously described [94]. Each reaction was
p e r f o r m e di nt r i p l i c a t ea n dt h ea v e r a g eC tv a l u ew a s
used in all analyses.
The relative gene expression level was calculated using
the Relative Standard Curve Method (see Guide to Per-
forming Relative Quantitation of Gene Expression Using
Real-time Quantitative PCR, Applied Biosystems). Stan-
dard curves were generated for target assay and for each
endogenous control assay by the association between
the Ct values and different quantities (5 serial dilution
steps) of a “calibrator” cDNA. The “calibrator” was pre-
pared by mixing small quantities of all experimental
samples. Expression values of the target and the control
genes were extrapolated from their respective standard
curves. Relative expression of target genes was com-
puted as the ratio of the target mRNA levels to the geo-
metric mean of the four endogenous controls: b-
glucuronidase (GUSB), cyclophilin A (PP1A), b2-micro-
globulin (b2M), and ribosomal protein, large, P0
(RPLP0) which were picked for their stability using geN-
orm [95,96]. Samples with Ct values > 33 were consid-
e r e do u t s i d et h er a n g eo fs e n s i t i v i t yo ft h ea s s a ya n d
were not included in the analyses.
Protein Quantitation
Protein expression studies were carried out to determine
whether different levels of RXRa gene expression were
reflected in the expression level of RXRa protein.
Because of the inherently lower reproducibility and
higher variability characteristic of Westerns in postmor-
tem tissue relative to qPCR, we restricted RXRa protein
analyses to cases with most robust changes in gene
expression. Therefore, a subset of the hippocampal sam-
ples (N = 30) studied for mRNA expression was ana-
lyzed by Western blotting to reflect broad variations in
gene expression. As fewer protein analyses were per-
formed than gene analyses, adjacent categories for all
t h r e ei n d i c e so fd i s e a s es e v e r i t y( s e eb e l o w )f o rg e n e
expression analyses were combined to achieve suffi-
ciently large sample sizes for comparisons (Table 3).
Tissue Lysate Preparation
Total tissue lysates were prepared from frozen hippo-
campal specimens from sister aliquots of the same brain
s a m p l e sa st h o s eu s e df o rq P C Ra n a l y s i sa sd e s c r i b e d
previously [41]. Total protein concentration of the lysate
was determined using a CBQCA Quantitation Kit
(Molecular Probes, Eugene, OR) with fluorescence mea-
sured on a SpectraMAX Gemini XS spectrofluorometer
(Molecular Devices, Sunnyvale, CA).
Western Blot Analysis
For gel electrophoresis, 10 μg of total protein was mixed
with loading buffer and loaded onto pre-cast 10-20%
Tris-glycine gels (Bio-Rad Laboratories, Hercules, CA),
and run at 150 V for 1 hr. Each gel was loaded with
three experimental samples in triplicate and “standard
tissue homogenate” (the mix of small aliquots of tissue
from all samples), run in quadruplicates. Separated pro-
teins were transferred to polyvinylidene difluoride
Table 3 Group classifications for protein expression
analysis
Protein Expression Analysis in the hippocampus
CDR Groups Dementia Severity Number of
individuals
0 No dementia 8
0.5 Questionable dementia 6
1-2 Mild/moderate dementia 6
3-5 Severe dementia/terminal
dementia
10
Braak Groups Braak stages
0-I None/Mild transentorhinal 8
II Severe transentorhinal 8
III-1V Limbic/Hippocampal CA1 7
V-VI Isocortical/Primary sensory
areas
7
NP Density
Groups
Plaques (number/mm2)
10 1 2
2-5 1 and more 18
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Page 11 of 14membranes at 100 V for 1 hour and probed with anti-
RXRa antibody (Abcam, Cambridge, MA) diluted
1:5,000 in 3% non-fat dry milk in TBS overnight at 4°C
with gentle shaking. To ensure equal protein loading
between individual samples, membranes were also incu-
bated with an anti-valosin containing protein (VCP)
antibody. VCP, a 97 kDa protein, has been previously
validated as reliable internal standard [97]. Following 1
hour incubation with the fluorescently-labeled secondary
antibodies, blots were scanned and quantified using the
Odyssey IR imaging system (LI-COR Biosciences, Lin-
coln, NE). RXRa signal was first normalized to the cor-
responding average signal for the standard tissue
homogenate and then for the VCP band from the same
sample. The linearity of the dose responses for the anti-
bodies used was established in preliminary experiments.
Statistical Analyses
We performed a logarithmic transformation of LXRb
and RXRa gene expression to eliminate heterogeneity,
a n du s e dt h et r a n s f o r m e dg e n ee x p r e s s i o nv a l u e sf o ra l l
subsequent statistical analyses. A preliminary analysis
assessed linear associations with gender, pH, PMI and
RIN to evaluate their use as covariates. In addition, age,
the most significant risk factor for dementia and a criti-
cal determinant of the extent of AD associated neuro-
pathology, was used as a covariate in all analyses
regardless of its association with the dependent variable.
We determined the linear association LXRb and RXRa
gene expression with CDR, Braak stages and NP density
by partial correlation analyses, controlling for potential
covariates if preliminary analyses showed significant cor-
relation with the expression level of the gene under ana-
lysis. Because the associations of each of these
interrelated scales with gene expression is at least partly
mediated through the associations with the other two
scales, additional partial correlation analyses assessed
each scale controlling also for the other two scales.
In order to determine non-linear association of CDR
Braak stages, and NP density with LXRb and RXRa gene
expression, each of these disease severity indices was
classified as a categorical variable. ANCOVA was per-
formed for each categorical variable controlling for age
and any other potential covariates. Another ANCOVA
for each categorical variable controlled also for other
two variables as scales, similar to the partial correlation
analyses.
Analyses for protein expression were the same as for
gene expression. All analyses were performed with SPSS
17.0 (SPSS, Chicago, IL).
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